Dannehl, D.; Engler, T.; Volmer, L.L.; Staebler, A.; Fischer, A.K.; Weiss, M.; Hahn, M.; Walter, C.B.; Grischke, E.-M.; Fend, F.;
et al. Recurrence Score® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial. Cancers 2022, 14, 5365.
https://doi.org/10.3390/cancers14215365
AMA Style
Dannehl D, Engler T, Volmer LL, Staebler A, Fischer AK, Weiss M, Hahn M, Walter CB, Grischke E-M, Fend F,
et al. Recurrence Score® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial. Cancers. 2022; 14(21):5365.
https://doi.org/10.3390/cancers14215365
Chicago/Turabian Style
Dannehl, Dominik, Tobias Engler, Lea L. Volmer, Annette Staebler, Anna K. Fischer, Martin Weiss, Markus Hahn, Christina B. Walter, Eva-Maria Grischke, Falko Fend,
and et al. 2022. "Recurrence Score® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial" Cancers 14, no. 21: 5365.
https://doi.org/10.3390/cancers14215365
APA Style
Dannehl, D., Engler, T., Volmer, L. L., Staebler, A., Fischer, A. K., Weiss, M., Hahn, M., Walter, C. B., Grischke, E. -M., Fend, F., Taran, F. -A., Brucker, S. Y., & Hartkopf, A. D.
(2022). Recurrence Score® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial. Cancers, 14(21), 5365.
https://doi.org/10.3390/cancers14215365